4.6 Review

RAD52: Paradigm of Synthetic Lethality and New Developments

期刊

FRONTIERS IN GENETICS
卷 12, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fgene.2021.780293

关键词

Rad52; homologous recombination; single strand annealing; break induced replication; synthetic lethality

资金

  1. National Cancer Institute of the National Institutes of Health (NIH) [CA188347, CA237286]
  2. National Institute of General Medical Sciences [GM136717]
  3. Department of Defense [BC191160]
  4. Cancer Prevention & Research Institute of Texas [RR210023]

向作者/读者索取更多资源

DNA double-strand breaks and inter-strand cross-links are the most harmful types of DNA damage that lead to genomic instability and cancer development. Rad52, a key HR protein in eukaryotes, has been found to play critical roles in backup DNA repair pathways in HR-deficient cancer cells. Recent studies have revealed RAD52's biochemical activities and its importance in multiple DNA repair processes.
DNA double-strand breaks and inter-strand cross-links are the most harmful types of DNA damage that cause genomic instability that lead to cancer development. The highest fidelity pathway for repairing damaged double-stranded DNA is termed Homologous recombination (HR). Rad52 is one of the key HR proteins in eukaryotes. Although it is critical for most DNA repair and recombination events in yeast, knockouts of mammalian RAD52 lack any discernable phenotypes. As a consequence, mammalian RAD52 has been long overlooked. That is changing now, as recent work has shown RAD52 to be critical for backup DNA repair pathways in HR-deficient cancer cells. Novel findings have shed light on RAD52's biochemical activities. RAD52 promotes DNA pairing (D-loop formation), single-strand DNA and DNA:RNA annealing, and inverse strand exchange. These activities contribute to its multiple roles in DNA damage repair including HR, single-strand annealing, break-induced replication, and RNA-mediated repair of DNA. The contributions of RAD52 that are essential to the viability of HR-deficient cancer cells are currently under investigation. These new findings make RAD52 an attractive target for the development of anti-cancer therapies against BRCA-deficient cancers.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据